PT - JOURNAL ARTICLE AU - LM Torrado García AU - B Rincón-Orozco AU - R Martínez-Vega AU - A Olmo TI - 237 Association between high risk human papillomavirus infection and sexual transmission diseases in women of the metropolitan area of bucaramanga AID - 10.1136/ijgc-2019-IGCS.237 DP - 2019 Sep 01 TA - International Journal of Gynecologic Cancer PG - A102--A102 VI - 29 IP - Suppl 3 4099 - http://ijgc.bmj.com/content/29/Suppl_3/A102.1.short 4100 - http://ijgc.bmj.com/content/29/Suppl_3/A102.1.full SO - Int J Gynecol Cancer2019 Sep 01; 29 AB - Objectives To evaluate the association between sexually transmitted diseases and HPV infection in women from the metropolitan area of Bucaramanga.Methods Cross-sectional study in women aged 35 to 65 years who were previously screened for HPV because they presented risk factors for developing cervical cancer through an epidemiological survey. Detection of species and serovars of Chlamydia trachomatis, Haemophilus ducreyi, Herpesvirus simple (HSV-1/HSV 2), Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis and Ureaplasma (urealyticum/parvum) using multiplex PCR and Specific hybridization (STD Direct Flow CHIP). For convenience, 419 samples were collected from September 2016 to November 2018 and prevalence ratios (PR) were measured to find associations.Results The prevalence of HPV-HR with at least one „genotype was 27.2% (n=114). The main STD detected in women with HPV-HR infection were Ureaplasma urealyticum/parvum (78.04%), Mycoplasma hominis (43.68%), „Trichomonas vaginalis (20.3%), and Herpes simplex virus type II (7.88%). The PR showed statistically significant „differences between HPV-HR and STD infections such as: Mycoplasma hominis (PR: 2.58, p: <0.0001), Trichomonas vaginalis (PR: 2.56, p<0.0001), Herpes Simplex type II (RP: 1.77, p: <0.0001).Conclusions Mycoplasma hominis, Trichomonas vaginalis and Herpes simplex virus type II are the most frequent coinfection in HPV-HR+ women, and an interesting topic to correlate with cervical cancer development.